A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis

Pelz, Joerg; Doerfer, J; Hohenberger, Werner; Meyer, Thomas

doi:10.1186/1471-2407-5-56

Cited by 36 publications

(45 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only two animals did not show any tumour expression. These findings differ from the results of Pelz et al [7], who found peritoneal surface malignancy in 100%, and Los et al [8], who only found this in 80% of their animals after i.p. inoculation.…”

Section: Discussioncontrasting

confidence: 76%

“…Following preliminary tests, our group also induced peritoneal carcinomatosis by subperitoneal injection of tumour cell suspension in the upper right quadrant after laparotomy according to the methods of Pelz et al [7]. We found a peritoneal surface malignancy 21 days after induction in 73 animals (97.3%).…”

Section: Discussionmentioning

confidence: 96%

“…However, only specific therapeutic steps were analysed, especially the efficacy of certain medications on intraperitoneal tumour growth [7][8][9][10].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

First surgical tumour reduction of peritoneal surface malignancy in a rat’s model

Hartmann

Kilian

Atanassov

et al. 2008

Clin Exp Metastasis

View full text Add to dashboard Cite

Surgical therapy of peritoneal surface malignancy from colorectal origin in combination with Hyperthermic Intraoperative Peritoneal Chemotherapy (HIPEC) has now become an established treatment approach in very few specialised centres. A peritonectomy procedure is possible to perform with additional HIPEC in patients. An experimental model to simulate peritonectomy procedure and HIPEC does not exist so far in rats. Nevertheless, animal models seem to be very important for evaluation of new therapeutic opportunities and toxicity of different multimodal therapies. In a first step we analysed the surgical tumour debulking of peritoneal surface malignancy in rats. A peritoneal surface malignancy from colonic origin was induced in 75 male BD IX rats. Twenty one days after induction of peritoneal surface malignancy rats were randomised and animals intend to create an operation with surgical tumour debulking. There was no tumour growth in two animals. The aim of the peritonectomy procedure was the complete tumour reduction. In this study the results of the surgical approach will be described. A complete tumour reduction (R0) was achieved in 34 animals. In 39 rats a macroscopic tumour deposit was left behind (R2). The intraoperative experimental Peritoneal Cancer Index (ePCI) was used to describe tumour weight and number of tumour inoculations. Both parameters were found to be dependent factors of complete tumour reduction. Six animals died due to therapeutical interventions. Surgical tumour debulking in rats with peritoneal surface malignancy is possible with high reliability and a low mortality rate. This animal model could be an important step for investigation of multimodal treatment options and toxicity in treatment regimens of peritoneal surface malignancy.

show abstract

Section: Discussioncontrasting

confidence: 76%

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

First surgical tumour reduction of peritoneal surface malignancy in a rat’s model

Hartmann

Kilian

Atanassov

et al. 2008

Clin Exp Metastasis

View full text Add to dashboard Cite

show abstract

“…Hyperthermia cytotoxic effect is exerted primarily through inhibition of functions essential to DNA replication, transcription and repair [43,44]. However, the synergistic anti-tumor effect of combined hyperthermia and intraperitoneal chemotherapy provides the rationale for the current treatment approach to peritoneal carcinomatosis [41,45]. This synergistic cytotoxic effect of intraperitoneal hyperthermic (42-438C) chemotherapy is an effective method for eradicating residual peritoneal surface disease up to 2.5 mm remaining in the abdomen after CCR0-1 (Table II) CRS.…”

Section: The Rational For Cytoreductive Surgery and Hyperthermic Intrmentioning

confidence: 99%

Evidence‐based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future

Nissan

Stojadinovic

Garofalo³

et al. 2009

Journal of Surgical Oncology

View full text Add to dashboard Cite

The current treatment of peritoneal surface malignancies (PSMs) is moving from a nihilistic approach, into a combined modality approach offering selected patients long-term survival. As primary PSM are rare, extrapolation of data from clinical trials of related disease is necessary to develop treatment guidelines. Secondary PSM are more common, and therefore, treatment guidelines should be developed based on prospective clinical trials. We reviewed the published and ongoing clinical trials studying the treatment of PSM.

show abstract

“…Second, this model needed to be validated, and thirdly, the technique of surgical cytoreduction had to be tested and improved. Several studies have described a peritoneal carcinomatosis model in mice and rats [6,8] , either with syngeneic or xenogeneic transplanted cancer cells. The application of the molecular optical imaging modality known as bioluminescence imaging (BLI) in a similar model has recently been described [9] , but its efficacy in tumor load scoring has not been tested.…”

mentioning

confidence: 99%

Bioluminescence as Gold Standard for Validation of Optical Imaging Modalities in Peritoneal Carcinomatosis Animal Models

Harlaar

Hesselink²,

Jong³

et al. 2010

Eur Surg Res

View full text Add to dashboard Cite

Background: The outcome of cytoreductive surgery in patients with peritoneal carcinomatosis is influenced by incomplete resection as a result of inadequate detection of a tumor, i.e. residual disease. The future perspective of complete resection, made possible by application of intraoperative near-infrared fluorescence imaging (NIRF), led to the development and validation of a bioluminescent colorectal peritoneal carcinomatosis xenograft rat model to act as the gold standard for the evaluation of new optical imaging modalities. Methods: Twenty nude rats were inoculated intraperitoneally with 2 × 10⁶ luciferase-labeled human colorectal tumor cells (HT-29-luc-D6). The peritoneal carcinomatosis index (PCI) was estimated using visual observation (PCI-VO) and VO combined with bioluminescence imaging (PCI-BLI). Subsequently, the BL images were presented, and residual tumor tissue was localized by PCI-BLI scoring and compared with the PCI-VO. Results: BLI revealed additional tumor tissue, confirmed by HE staining, compared to VO alone in 7 out of 8 rats (p < 0.02). Conclusion: The developed model turned out to be suitable. The use of BLI for tumor detection was more sensitive compared to VO alone. In this model, BLI significantly detected residual disease, and therefore, BLI can be denominated as the gold standard for the evaluation of optical imaging modalities like NIRF.

show abstract

A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis

Cited by 36 publications

References 14 publications

First surgical tumour reduction of peritoneal surface malignancy in a rat’s model

First surgical tumour reduction of peritoneal surface malignancy in a rat’s model

Evidence‐based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future

Bioluminescence as Gold Standard for Validation of Optical Imaging Modalities in Peritoneal Carcinomatosis Animal Models

Contact Info

Product

Resources

About